At the news
? BULLISHIMPACT 7/10 6-K filed Jul 15, 2026 at 09:11 ET
GSK completed its $10.6B acquisition of Nuvalent, adding three lung cancer assets (zidesamtinib, neladalkib, NVL-330) with near-term FDA review decisions. The deal is a major strategic expansion into NSCLC, with multi-blockbuster potential if approved.
- GSK completed acquisition of Nuvalent for aggregate equity value of approximately $10.6 billion (£8.0 billion); net of cash acquired, GSK's aggregate investment is approximately $9.4 billion (£7.1 billion).
- Acquisition adds three lung cancer assets: zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330 (phase I).
- Zidesamtinib and neladalkib are under FDA review for ROS1-positive and ALK-altered NSCLC with target decision dates later this year; both have Breakthrough Therapy and Orphan Drug Designations.
- If approved, assets are expected to launch in 2026 with multi-blockbuster potential.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access